Literature DB >> 19154567

Predictors of corticosteroid-dependent and corticosteroid-refractory inflammatory bowel disease: analysis of a Chinese cohort study.

D K L Chow1, J J Y Sung, K K F Tsoi, V W S Wong, J C Y Wu, R W L Leong, F K L Chan.   

Abstract

BACKGROUND: Patients with inflammatory bowel disease (IBD) who are corticosteroid-dependent or -refractory are at higher risk of developing disease- and treatment-related complications. AIMS: To identify retrospectively clinical factors present at diagnosis that predict the occurrence of corticosteroid dependency and refractoriness in Crohn's disease (CD) and ulcerative colitis (UC) patients.
METHODS: A total of 310 IBD patients (134 CD, 176 UC) were observed for 2140 person years and their use of systemic corticosteroids was determined. Outcomes of corticosteroid dependency and refractoriness were recorded. Univariate and multivariate analyses were performed to determine the clinical factors associated with outcomes.
RESULTS: Seventy-seven (57.5%) CD and 95 (54.0%) UC patients had received corticosteroids during study period. In CD, thrombocytosis [Hazard ratio (HR):3.0] predicted, whereas colonic CD (HR:0.3) negatively predicted corticosteroid dependency. Stricturing phenotype (HR:4.5) predicted corticosteroid-refractory CD. For UC, thrombocytosis (HR:3.9) and extensive colitis (HR:1.7) predicted corticosteroid dependency. Presence of anaemia (HR:10.8) at diagnosis and initial requirement of total parenteral nutrition (TPN) (HR:18.8) predicted corticosteroid-refractory UC. The cumulative risks of surgery were 17.8% and 5.4% for CD and UC patients respectively at 1 year after starting corticosteroids.
CONCLUSIONS: Thrombocytosis at diagnosis predicted corticosteroid-dependency in IBD. Stricturing phenotype of CD and the presence of anaemia in UC predicted subsequent course of corticosteroid refractoriness.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19154567     DOI: 10.1111/j.1365-2036.2009.03944.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

1.  Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort.

Authors:  Steven F G Jeuring; Vince B C Biemans; Tim R A van den Heuvel; Maurice P Zeegers; Wim H Hameeteman; Mariëlle J L Romberg-Camps; Liekele E Oostenbrug; Ad A M Masclee; Daisy M A E Jonkers; Marieke J Pierik
Journal:  Am J Gastroenterol       Date:  2018-01-09       Impact factor: 10.864

2.  Predictors of Outcome in Ulcerative Colitis.

Authors:  Matti Waterman; Jo Knight; Amreen Dinani; Wei Xu; Joanne M Stempak; Kenneth Croitoru; Geoffrey C Nguyen; Zane Cohen; Robin S McLeod; Gordon R Greenberg; A Hillary Steinhart; Mark S Silverberg
Journal:  Inflamm Bowel Dis       Date:  2015-09       Impact factor: 5.325

3.  Corticosteroid therapy in ulcerative colitis: Clinical response and predictors.

Authors:  Jin Li; Fan Wang; Hong-Jie Zhang; Jian-Qiu Sheng; Wen-Feng Yan; Min-Xing Ma; Ru-Ying Fan; Fang Gu; Chuan-Feng Li; Da-Fan Chen; Ping Zheng; Yu-Pei Gu; Qian Cao; Hong Yang; Jia-Ming Qian; Pin-Jin Hu; Bing Xia
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

4.  Short-Term Clinical Response to Corticosteroids Can Predict Long-Term Natural History of Ulcerative Colitis: Prospective Study Experience.

Authors:  Tarun Rai; Bikash Narayan Choudhury; Saurabh Kedia; Sawan Bopanna; Pratap Mouli Venigalla; Sushil Kumar Garg; Vikas Singla; Govind Makharia; Vineet Ahuja
Journal:  Dig Dis Sci       Date:  2017-02-04       Impact factor: 3.199

5.  Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases.

Authors:  Anthony Buisson; Wing Yan Mak; Michael J Andersen; Donald Lei; Stacy A Kahn; Joel Pekow; Russel D Cohen; Nada Zmeter; Bruno Pereira; David T Rubin
Journal:  J Crohns Colitis       Date:  2019-08-14       Impact factor: 9.071

6.  Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia.

Authors:  Stefanie Kulnigg-Dabsch; Rayko Evstatiev; Clemens Dejaco; Christoph Gasche
Journal:  PLoS One       Date:  2012-04-10       Impact factor: 3.240

7.  Family history and disease outcomes in patients with Crohn's disease: A comparison between China and the United States.

Authors:  Pei-Qi Wang; Jun Hu; Elie S Al Kazzi; Eboselume Akhuemonkhan; Min Zhi; Xiang Gao; Raquel Holand de Paula Pessoa; Sami Ghazaleh; Tuhina Cornelius; Suhel Abbas Sabunwala; Shadi Ghadermarzi; Kartikeya Tripathi; Mark Lazarev; Pin-Jin Hu; Susan Hutfless
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-11-06

8.  Clinical predictors for a complicated course of disease in an inception cohort of patients with ulcerative colitis: results from the prospective, observational EPICOL study.

Authors:  Carsten Schmidt; Bernd Bokemeyer; Andreas Lügering; Dominik Bettenworth; Niels Teich; Imma Fischer; Leonie Hammer; Stefanie Kolterer; Stefan Rath; Andreas Stallmach
Journal:  Int J Colorectal Dis       Date:  2022-01-27       Impact factor: 2.571

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.